Silver Book Fact

Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection

Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham. Identification of Urine Biomarkers for AMD. Invest Opthalmol Vis Sci. 2011; 52(7): 4639-4644

Reference

Title
Identification of Urine Biomarkers for AMD
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham
Volume & Issue
Volume 52, Issue 7
Pages
4639-4644

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Treatments that have been found to delay or prevent diabetic retinopathy save the U.S. $1.6 billion annually.